tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jan 4.
doi: 10.1002/jmv.27573. Online ahead of print.
Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab
Kyriacos Evangelou[SUP] 1 [/SUP], Sofia Rozani[SUP] 1 [/SUP], Christos Tsagkaris[SUP] 2 [/SUP]
Affiliations
Abstract
Monoclonal antibodies are antibodies highly monospecific for a particular antigen or an epitope, with a broad spectrum of clinical and experimental uses including autoimmune disease, cancer, bacterial and viral infection, asthma, atopic dermatitis and osteoporosis treatment. [SUP]2[/SUP] So far, five monoclonal antibodies with neutralizing action against epitopes of the SARS-CoV-2 spike protein have been approved for the treatment of COVID-19, namely bamlanivimab, casirivimab, etesevimab, imdevimab and sotrovimab. [SUP]3[/SUP] Nevertheless, COVID-19 detection and treatment has also been reported to overlap with the administration of other monoclonal antibodies aimed towards the management of thrombotic events. As a matter of fact, we deploy the example of abciximab to highlight the importance of retaining pragmatism apropos of ground-breaking treatment options. [SUP]4[/SUP] This article is protected by copyright. All rights reserved.
Keywords: Coronavirus < Virus classification; Pandemics < Epidemiology; SARS coronavirus < Virus classification.
. 2022 Jan 4.
doi: 10.1002/jmv.27573. Online ahead of print.
Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab
Kyriacos Evangelou[SUP] 1 [/SUP], Sofia Rozani[SUP] 1 [/SUP], Christos Tsagkaris[SUP] 2 [/SUP]
Affiliations
- PMID: 34984684
- DOI: 10.1002/jmv.27573
Abstract
Monoclonal antibodies are antibodies highly monospecific for a particular antigen or an epitope, with a broad spectrum of clinical and experimental uses including autoimmune disease, cancer, bacterial and viral infection, asthma, atopic dermatitis and osteoporosis treatment. [SUP]2[/SUP] So far, five monoclonal antibodies with neutralizing action against epitopes of the SARS-CoV-2 spike protein have been approved for the treatment of COVID-19, namely bamlanivimab, casirivimab, etesevimab, imdevimab and sotrovimab. [SUP]3[/SUP] Nevertheless, COVID-19 detection and treatment has also been reported to overlap with the administration of other monoclonal antibodies aimed towards the management of thrombotic events. As a matter of fact, we deploy the example of abciximab to highlight the importance of retaining pragmatism apropos of ground-breaking treatment options. [SUP]4[/SUP] This article is protected by copyright. All rights reserved.
Keywords: Coronavirus < Virus classification; Pandemics < Epidemiology; SARS coronavirus < Virus classification.
